Alzamend Neuro Inc (ALZN) Peer Comparison
$1.66
$-0.04
(-2.35%)
As on 04-Sep-2026 16:20EDT
Market cap
$8 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
10.8
Div. Yield
0 %
Edit
| Alzamend Neuro Inc (ALZN) | Anixa Biosciences (ANIX) | Champions Oncology (CSBR) | Biovie Inc (BIVI) | Bio-Techne Corp (TECH) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
8 | 104 | 73 | 17 | 11,358 |
Revenue ($ Mln) |
-- | -- | 59 | -- | 1,215 |
Net Profit ($ Mln) |
-8.77 | -10.07 | -1.18 | -22.07 | 181.86 |
Net Margin (%) |
-- | -- | -1.98 | -- | 14.97 |
RoE (%) |
-373.18 | -67.38 | -30.48 | 0.00 | 9.03 |
Price to Earnings |
-- | -- | -- | -- | 62.44 |
Price-To-Book |
10.77 | 7.15 | 17.67 | 1.85 | 5.38 |
Income Statement ($ Mln)
| Alzamend Neuro Inc (ALZN) | Anixa Biosciences (ANIX) | Champions Oncology (CSBR) | Biovie Inc (BIVI) | Bio-Techne Corp (TECH) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
0.00 | -- | 59.43 | 0.00 | 1,215.04 |
|
Cost of Revenue
|
-- | -- | 30.90 | -- | 415.97 |
|
Gross Profit
|
-- | -- | 28.53 | -- | 799.07 |
|
Operating Expenses
|
8.77 | -- | 29.67 | 22.65 | 547.18 |
|
Operating Profit (EBIT)
|
-8.77 | -- | -1.14 | -22.65 | 251.89 |
|
Other Income
|
-- | -- | -- | -- | -- |
|
Profit before Tax
|
-8.77 | -- | -0.93 | -22.07 | 240.68 |
|
Provision for Tax
|
-- | -- | 0.25 | -- | 58.82 |
|
Profit after Tax (Net Income)
|
-8.77 | -- | -1.18 | -22.07 | 181.86 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Consolidated Profit
|
-- | -- | -- | -- | -- |
Liabilities ($ Mln)
| Alzamend Neuro Inc (ALZN) | Anixa Biosciences (ANIX) | Champions Oncology (CSBR) | Biovie Inc (BIVI) | Bio-Techne Corp (TECH) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
0.73 | -- | 3.94 | 10,270,270.00 | 2,108.22 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Non-Current Liabilities
|
0.00 | -- | 3.00 | 184,421.00 | 407.07 |
|
Current Liabilities
|
1.35 | -- | 19.92 | 3,795,771.00 | 163.70 |
|
Total Liabilities
|
2.08 | -- | 26.99 | 14,250,462.00 | 2,678.99 |
Assets ($ Mln)
| Alzamend Neuro Inc (ALZN) | Anixa Biosciences (ANIX) | Champions Oncology (CSBR) | Biovie Inc (BIVI) | Bio-Techne Corp (TECH) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
0.31 | -- | 7.77 | 608,297.00 | 1,934.59 |
|
Current Assets
|
1.76 | -- | 19.22 | 13,642,165.00 | 744.40 |
|
Total Assets
|
2.08 | -- | 26.99 | 14,250,462.00 | 2,678.99 |
|
Total Debt*
|
-- | -- | 4.51 | 275,430.00 | 289.09 |
|
Net Current Assets
|
0.42 | -- | -0.70 | 9.85 | 580.70 |
Cashflow ($ Mln)
| Alzamend Neuro Inc (ALZN) | Anixa Biosciences (ANIX) | Champions Oncology (CSBR) | Biovie Inc (BIVI) | Bio-Techne Corp (TECH) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-8.07 | -- | -4.47 | -19,024.81 | 292.07 |
|
Cash Flow from Investing Activities
|
-- | -- | -0.54 | -- | -18.19 |
|
Cash from Financing Activities
|
4.83 | -- | 0.10 | 10,457.63 | -169.11 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Alzamend Neuro Inc (ALZN) | Anixa Biosciences (ANIX) | Champions Oncology (CSBR) | Biovie Inc (BIVI) | Bio-Techne Corp (TECH) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-373.18 | -- | -12.82 | 0.00 | 7.64 |
|
ROE (%)
|
-373.18 | -- | -30.48 | 0.00 | 9.03 |
|
ROA (%)
|
-262.55 | -- | -3.96 | 0.00 | 6.95 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-- | -- | -1.98 | -- | 14.97 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Alzamend Neuro Inc (ALZN) | Anixa Biosciences (ANIX) | Champions Oncology (CSBR) | Biovie Inc (BIVI) | Bio-Techne Corp (TECH) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-- | -- | 0.04 | -- | 0.00 |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
-94.30 | -- | -124.99 | -25.83 | 147.77 |
|
EPS Growth (%)
|
-- | -- | -- | -1.46 | 1.46 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Alzamend Neuro Inc (ALZN) | Anixa Biosciences (ANIX) | Champions Oncology (CSBR) | Biovie Inc (BIVI) | Bio-Techne Corp (TECH) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-- | -- | -- | -0.66 | 61.00 |
|
Price / Book Value
|
-- | -- | -- | 0.00 | 5.26 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
0.08 | -- | -0.80 | 397,772.83 | 32.37 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Alzamend Neuro Inc (ALZN) | Anixa Biosciences (ANIX) | Champions Oncology (CSBR) | Biovie Inc (BIVI) | Bio-Techne Corp (TECH) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
-- | -- | 1.15 | 0.03 | 0.14 |
|
Short term debt to equity ratio
|
-- | -- | 0.39 | 0.01 | 0.01 |
|
Current Ratio
|
1.31 | -- | 0.96 | 3.59 | 4.55 |
|
Quick Ratio
|
-- | -- | -- | -- | 3.35 |
|
Interest Coverage
|
-1,324.33 | -- | -- | -1,232.05 | 45.53 |
Operating Efficiency Ratios
| Alzamend Neuro Inc (ALZN) | Anixa Biosciences (ANIX) | Champions Oncology (CSBR) | Biovie Inc (BIVI) | Bio-Techne Corp (TECH) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
-- | -- | 22.18 | -- | 18.15 |
|
Asset Turnover
|
0.00 | -- | 2.00 | 0.00 | 0.46 |
|
Receivable days
|
-- | -- | 75.02 | -- | 64.24 |
|
Inventory Days
|
-- | -- | -- | -- | 169.11 |
|
Payable days
|
-- | -- | 65.90 | -- | 22.83 |
|
Cash Conversion Cycle
|
-- | -- | -- | -- | 210.51 |
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
